

Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes

Assessment of the physical dependence potential of difelikefalin: randomized placebo-controlled study in patients receiving hemodialysis

Spencer RH, Munera C, Shram MJ, Menzaghi F. Assessment of the physical dependence potential of difelikefalin: randomized placebo-controlled study in patients receiving hemodialysis. Published online May 1, 2023. *Clin Transl Sci*. doi:10.1111/cts.13538

Link: <https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13538>

Difelikefalin for treating pruritus in people having hemodialysis

Committee B Members and NICE Project Team. Difelikefalin for treating pruritus in people having haemodialysis. National Institute for Health and Care Excellence (NICE). May 17, 2023.

<https://www.nice.org.uk/guidance/ta890>

Link: <https://www.nice.org.uk/guidance/ta890>

The first real-world experience of IV difelikefalin to treat chronic kidney disease-associated pruritus in hemodialysis patients

Kraft L, Schanz M, Schricker S, et al. The first real-world experience of IV difelikefalin to treat chronic kidney disease-associated pruritus in haemodialysis patients. *J Eur Acad Dermatol Venereol*. 2023;37(8): e1059-e1061. doi:10.1111/jdv.19105

Link: <https://onlinelibrary.wiley.com/doi/10.1111/jdv.19105>

Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 phase 3 studies

Topf J, Wooldridge T, McCafferty K, et al. Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 phase 3 studies. *Kidney Med*. 2022;4(8):100512. doi:10.1016/j.xkme.2022.100512

Link: [https://www.kidneymedicinejournal.org/article/S2590-0595\(22\)00133-9/fulltext](https://www.kidneymedicinejournal.org/article/S2590-0595(22)00133-9/fulltext)

Safety and tolerability of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis from the phase 3 clinical trial program

Fishbane S, Wen W, Munera C, et al. Safety and tolerability of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis from the phase 3 clinical trial program. *Kidney Med.* 2022;4(8):100513. doi:10.1016/j.xkme.2022.100513

Link: <https://www.sciencedirect.com/science/article/pii/S2590059522001340>

S2k guideline: Diagnosis and treatment of chronic pruritus

Ständer S, Zeidler C, Augustin M, et al. S2k guideline: diagnosis and treatment of chronic pruritus. *J Dtsch Dermatol Ges.* 2022;20(10):1387-1402. doi:10.1111/ddg.14830

Link: <https://onlinelibrary.wiley.com/doi/full/10.1111/ddg.14830>

Clinically meaningful change in itch intensity scores: an evaluation in patients with chronic kidney disease-associated pruritus

Vernon M, Ständer S, Munera C, Spencer RH, Menzaghi F. Clinically meaningful change in itch intensity scores: An evaluation in patients with chronic kidney disease-associated pruritus. *J Am Acad Dermatol.* 2021;84(4):1132-1134. doi:10.1016/j.jaad.2020.06.991

Link: [https://www.jaad.org/article/S0190-9622\(20\)32091-0/fulltext](https://www.jaad.org/article/S0190-9622(20)32091-0/fulltext)

A phase 3 trial of difelikefalin in hemodialysis patients with pruritus

Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F; KALM-1 Trial Investigators. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. *N Engl J Med.* 2020;382(3):222-232. doi:10.1056/NEJMoa1912770

Link: <https://www.nejm.org/doi/10.1056/NEJMoa1912770>